1. Home
  2.  » 
  3. Expert Content
  4.  » Cell Therapy

EXPERT CONTENT

Downloadable expert content covering integrated, tailored solutions to accelerate your path to market.

VISIT OUR YOUTUBE CHANNEL

EXPERT CONTENT

Downloadable expert content covering integrated, tailored solutions to accelerate your path to market.

VISIT OUR YOUTUBE CHANNEL

BROWSE BY

TOPIC:








TYPE:












An Interview: Potential of iPSCs

Summary: In this informative interview with Phacilitate, Boris Greber and Thomas Marx answer questions about the position of induced pluripotent stem cells in today’s advanced therapies market and the transformative power latent in their clinical application.

read more

Cellular Starting Materials In Focus

Summary: In this ebook, we bring you expert insights into the advantages that various cellular starting materials have, with a particular focus on human induced pluripotent stem cells (iPSCs).

read more

An Interview: Spotlight on iPSCs

Summary: Catalent and RegMedNet showcase how induced pluripotent stem cells can catalyze the advancement of novel cell therapies. This feature explores biological, clinical and commercial characteristics of iPSCs as ideal starting materials.

read more

Features of iPSCs as Starting Materials

Summary: How can using iPSCs as starting materials help with transforming cell therapies into standard care? This infographic highlights the key features of iPSCs as starting materials, from donor consent through to commercial innovation.

read more

CAR-T Therapy: An Integrated Approach with an Experienced Partner

Summary: CAR-T cell therapies require expertise in process development to successfully scale-up manufacturing. Working with an integrated partner like Catalent gives you the ability to manufacture at clinical and commercial scale efficiently and effectively for both autologous and allogeneic cell therapies.

read more

Manufacturing Innovation Across New Modalities

Summary: The successful outcomes delivered by cell and gene therapies coupled with emergence of modalities across nucleic acid therapeutics and microbiomes pose the next challenge for innovators to make these new modalities…

read more

Pharma Predictions for 2021

Summary: Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.

read more

Cell and Gene Therapy Brochure

Summary: Catalent Cell & Gene Therapy is a premier partner for innovators across the entire field of advanced biotherapeutics. Explore our development and manufacturing capabilities for allogeneic and autologous cell therapies, viral vector-based…

read more